MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
2.680
-0.030
-1.11%
After Hours: 2.730 +0.05 +1.87% 16:59 12/19 EST
OPEN
2.770
PREV CLOSE
2.710
HIGH
2.875
LOW
2.680
VOLUME
70.57K
TURNOVER
--
52 WEEK HIGH
20.59
52 WEEK LOW
2.450
MARKET CAP
11.36M
P/E (TTM)
-0.2487
1D
5D
1M
3M
1Y
5Y
1D
Director John Neis Reports Disposal of Cellectar BioSciences Inc. Common Shares
Reuters · 3d ago
Cellectar Biosciences announces supply agreement with Ionetix
TipRanks · 3d ago
Cellectar BioSciences Signs Multi-Year Supply Agreement with Ionetix for Alpha-Emitting Isotopes
Reuters · 3d ago
Cellectar BioSciences Partners with Ionetix for Alpha-Emitting Isotope Supply
Reuters · 3d ago
CELLECTAR BIOSCIENCES INC - ANNOUNCES MULTI-YEAR SUPPLY AGREEMENT WITH IONETIX
Reuters · 3d ago
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Barchart · 3d ago
Weekly Report: what happened at CLRB last week (1208-1212)?
Weekly Report · 4d ago
Weekly Report: what happened at CLRB last week (1201-1205)?
Weekly Report · 12/08 10:23
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.